Association between Dose of Octreotide and Tumor Control in Gastroenteropancreatic Neuroendocrine Tumors

#909

Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) represent a heterogeneous group of tumors. Octreotide is used in the symptom control of NETs. The PROMID study demonstrated a benefit of octreotide on disease stabilization in midgut NETs, but a survival analysis was not possible due to insufficient events.

Aim(s): To determine if dose of octreotide correlates with outcomes.

Materials and methods: We reviewed all patients who were diagnosed between 1987-2013 and treated with octreotide at the BC Cancer Agency. We compared overall survival in patients who received low v. high dose octreotide.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Lau S, Cheung W,

Keywords: GI, NET, octreotide,

To read the full abstract, please log into your ENETS Member account.